September 04, 2025

New Headquarters – PL BioScience Announces Major Site Expansion in September 2025

New Headquarters – PL BioScience Announces Major Site Expansion in September 2025

Key Milestone for PL BioScience as new headquarters are announced

PL BioScience announced the next major step in its expansion – an upcoming move to a new 1,200 m² facility in Aachen, in September 2025. This key milestone will support the company’s growth and upscaling efforts, and provide the world’s largest HPL output, with 20,000L annual capacity to meet the rapidly growing global demand for safe, high-quality, animal-free cell culture supplements.

The new headquarters includes dedicated production and storage areas, alongside office space to accommodate the company’s continued growth, positioning it as the largest provider of HPL products worldwide. It will also provide more highly skilled jobs in the region.

“This is a major step forward for PL BioScience,” said Dr. Hatim Hemeda, CEO of the German biotech. “With the new headquarters, we are accelerating our growth and strengthening our future production capabilities in response to growing global demand for HPL products. In addition, this expansion marks a significant step toward accelerating product innovation, including the further development of our new artificial HPL, the world’s first scalable, fully lab-made HPL solution.”

The facility will serve as a hub for research and product innovation, supporting the development of next-generation HPL-based media, such as artificial HPL. Other advanced products are in development, including specialized products tailored to the needs of different cell manufacturing applications, such as CAR-T cell manufacturing.

Read the full press release here.

Our latest News

discover more
AlphaFold Database adds viral protein complexes to support pandemic preparedness

AlphaFold Database adds viral protein complexes to support pandemic preparedness

by Sera Guli The latest release includes protein structure predictions for thousands of viruses, which could improve the response to future outbreaks AI-predicted protein complex structures for over 2,800 viruses are now openly available in the AlphaFold Database. To better understand and protect against emerging pathogens, the dataset prioritises proteomes from viral families known to […]

European Commission grants €57 million to critical open data resources

European Commission grants €57 million to critical open data resources

Horizon Europe funding will support GENCODE, UniProt, and Europe PMC The European Commission has announced €57 million in funding to support GENCODE, UniProt, and Europe PMC. These life sciences data resources are delivered and managed by EMBL’s European Bioinformatics Institute (EMBL-EBI) alongside international partners. The financial support will be given in the shape of three […]

Harnessing Synthetic Cellular Systems as Immune Cell Boosters

Harnessing Synthetic Cellular Systems as Immune Cell Boosters

How can cell-based immunotherapies for cancer and autoimmune diseases become more widely available in the long term? The SYNTHIA project is addressing this challenge: The Max Planck Institute for Medical Research and the Fraunhofer Institute for Cell Therapy and Immunology IZI are collaborating on new research approaches to advance the development of cell-based immunotherapies. The […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp